p41-ARCa Inhibitors
The chemical class known as p41-ARCa inhibitors encompasses a group of compounds designed to selectively interact with a specific biological target, the p41-ARCa protein. This protein is part of a larger family of proteins that play crucial roles in various cellular processes. The precise biochemical function of p41-ARCa has been the subject of extensive research, and inhibitors that can modulate its activity are of significant interest in the field of molecular biology. The development of these inhibitors involves a deep understanding of the protein's structure and the key interaction points that are essential for its activity. Inhibitors in this class are typically characterized by their ability to bind to the active or allosteric sites of the p41-ARCa protein, which can lead to changes in the protein's conformation and, consequently, its function within the cell.
The design of p41-ARCa inhibitors is a sophisticated process that relies on a variety of techniques, including computational modeling, structure-activity relationship studies, and medicinal chemistry. These compounds can be small molecules or larger biologically-derived entities, and their chemical structures are often complex, reflecting the intricate nature of their target interactions. The specificity of p41-ARCa inhibitors is of utmost importance, as off-target effects can lead to unintended consequences within the cellular environment. As such, these inhibitors are tailored to achieve a high degree of precision in their binding affinity, ensuring that they engage with the p41-ARCa protein in a highly selective manner. Understanding the dynamic between the inhibitor and its target is critical, as this interplay dictates the compound's ability to effectively influence the protein's behavior without affecting other similar proteins in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is a kinase that phosphorylates and activates ERK in the MAPK/ERK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK, which can result in the downregulation of p41-ARCa activity, as p41-ARCa is a downstream effector in this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a kinase involved in the PI3K/AKT signaling pathway. By inhibiting PI3K, LY294002 suppresses the phosphorylation and activation of AKT, potentially leading to reduced activity of p41-ARCa, which may be regulated by AKT-mediated signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent PI3K inhibitor, which like LY294002, can prevent AKT activation. This disruption in the PI3K/AKT pathway could hinder any regulatory effect this pathway has on p41-ARCa, leading to its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. The p38 MAPK pathway is involved in response to stress signals. By inhibiting p38 MAPK, SB203580 could indirectly affect the functional activity of p41-ARCa if p41-ARCa is influenced by stress-activated signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which blocks the activation of ERK1/2 in the MAPK pathway. Inhibition of this pathway by U0126 could lead to a decrease in p41-ARCa activity if p41-ARCa is modulated by ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. Inhibiting JNK activity can influence the transcription factors that control the expression of genes including those that may regulate p41-ARCa. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. If p41-ARCa is regulated through proteasomal degradation, MG132 could lead to an accumulation of proteins that indirectly reduce p41-ARCa activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor, which could similarly lead to the accumulation of proteins that negatively regulate p41-ARCa through post-translational modifications or by competing for binding partners. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress the mTORC1 signaling pathway, which is involved in protein synthesis. If p41-ARCa is controlled by signaling through mTORC1, rapamycin could reduce its functional activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. If p41-ARCa activity is influenced by EGFR signaling, gefitinib's inhibition of this pathway would lead to a decrease in p41-ARCa activity. | ||||||